Artie Nelson, MD
Child & Adolescent Psychiatry · Birmingham, ALNPI 1972660827
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,905 of the $31,994 with a category attached, or 65.3%. AbbVie accounts for 65.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $10,194 and has fallen 84.9% since, to $1,544 in 2025. Among child & adolescent psychiatry clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $105.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$21K
- Corium, LLC$3K
- Neuronetics, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Johnson & Johnson$1K
- Axsome Therapeutics, Inc.$798
- plus $3K from 19 others
What the payments were for
- Consulting fees$3601%
- Speaking & faculty fees$20,90565%
- Travel & lodging$3561%
- Food & beverage$9,42429%
- Other$9503%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 111 | $20,881 |
| Corium, LLC | 15 | $2,603 |
| Neuronetics, Inc. | 11 | $1,641 |
| Otsuka America Pharmaceutical, Inc. | 47 | $1,606 |
| Johnson & Johnson | 20 | $1,195 |
| Axsome Therapeutics, Inc. | 11 | $798 |
| Alkermes, Inc. | 14 | $764 |
| MDD US Operations, LLC | 13 | $435 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $405 |
| Supernus Pharmaceuticals, Inc. | 10 | $353 |
| Tris Pharma Inc | 4 | $329 |
| Teva Pharmaceuticals USA, Inc. | 6 | $266 |
| Neurocrine Biosciences, Inc. | 3 | $182 |
| Ironshore Pharmaceuticals Inc. | 5 | $109 |
| Pfizer | 1 | $102 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $94 |
| Collegium Pharmaceutical, Inc. | 3 | $54 |
| Indivior Inc. | 2 | $40 |
| Alfasigma USA, Inc. | 2 | $37 |
| Noven Pharmaceuticals, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Rhodes Pharmaceuticals L.p. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $14 |
| Neos Therapeutics, LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$19,887
- Azstarys$2,405
- LYBALVI$1,418
- NEUROSTAR TMS THERAPY SYSTEM$1,197
- SPRAVATO$733
- REXULTI$730
- Auvelity$583
- ABILIFY MAINTENA$244
- QELBREE$214
- NEUROSTAR TMS THERAPY$181
- VIVITROL$125
- Onyda XR$125
- Lucemyra/Lofexidine$124
- INGREZZA$122
- Austedo XR$122
- ABILIFY ASIMTUFII$122
- AUSTEDO$111
- EUCRISA$102
How this compares
$31,994 in reported general payments places this provider in the 95th percentile of 40 child & adolescent psychiatry providers in Alabama.
See all child & adolescent psychiatry providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 18 | $24,388 |
| TrintellixVortioxetine Hydrobromide | 18 | $13,361 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $5,590 |
| AzstarysSerdexmethylphen/Dexmethylphen | 12 | $4,895 |
| Aripiprazole | 18 | $3,884 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 53 | $2,156 |
| Fluvoxamine Maleate | 23 | $1,095 |
| Clonazepam | 63 | $977 |
| Alprazolam | 123 | $803 |
| Olanzapine | 33 | $536 |
| Minocycline Hcl | 13 | $486 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $465 |
| Fluoxetine Hcl | 40 | $414 |
| Citalopram HbrCitalopram Hydrobromide | 26 | $396 |
| Lorazepam | 27 | $379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $20,881 | $24,38818 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $405 | $13,36118 claims |
| Corium, LLCAzstarys | $2,603 | $4,89512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 40 child & adolescent psychiatry providers in Alabama.
Other child & adolescent psychiatry in Birmingham
- Karen CallahanBirmingham$5K
- Casey LowreyBirmingham$4K
- Elizabeth FergusonBirmingham$1K
- Srilata AnneBirmingham$1K
- Stewart WaddellBirmingham$1K
- Abhishek WadhwaBirmingham$978
- Francisca MgbodileBirmingham$582
- James CullinanBirmingham$57
- Tom VaughanBirmingham$49
- Tolulope PetersBirmingham$35
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.